WVE insider trading
NasdaqGM HealthcareWave Life Sciences Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Company website: wavelifesciences.com
WVE insider activity at a glance
FilingIQ has scored 348 insider transactions for WVE since Aug 14, 2015. The most recent filing in our index is dated Mar 30, 2026.
Across the full history, 20 open-market purchases
and 141 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on WVE insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest WVE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding WVE
Frequently asked
- How many insider trades does FilingIQ track for WVE?
- FilingIQ tracks 348 Form 4 insider transactions for WVE (Wave Life Sciences Ltd.), covering filings from Aug 14, 2015 onwards. 12 of those were filed in the last 90 days.
- Are WVE insiders net buyers or net sellers?
- Across the full Form 4 history for WVE, 20 transactions (6%) were open-market purchases and 141 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does WVE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is WVE in?
- Wave Life Sciences Ltd. (WVE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.29B.
Methodology & sources
Every WVE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.